Table 1.
Healthcare utilization and costs summary.
See appendix A in S1 File for a detailed description of cost sources.
Table 2.
Patient demographics, disease and treatment information, overall and by intervention group.
Table 3.
Summaries of the Quality of Life Years (QALY) and costs, both overall and stratified by the study outcome (occurrence of a procedure tract metastasis, or PTM).
Fig 1.
Cost effectiveness plane and CEAC for the intervention.
The lines on the cost-effectiveness plane (left) represent willingness-to-pay thresholds of £20,000 (green) and £30,000 (purple). The same willingness to pay thresholds are marked with vertical dotted lines on the CEAC (right). The ellipses represent the area in which 95% of the bootstrap sample values fall.
Table 4.
Summary of the cost-effectiveness analysis, with incremental costs and QALYs, and the resultant ICER.
Fig 2.
Kaplan Meier curves for treatment and PTM event.
The survival rates for prophylactic treatment patients are presented in red, deferred treatment in blue. Patients that experienced a PTM are drawn with dashed lines, no-PTM patients with solid lines. At the bottom of the figure the number of patients at risk at each 100-day interval are noted. Some patients go beyond 365 days (study duration) due to the delay in scheduling their final appointment.